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ABSTRACT
Objective: To estimate the incremental cost-utility ratio
(ICUR) of rimonabant 20 mg/day in the treatment of obesity
from a third-party payer’s perspective.
Methods: Pooled data from three randomized clinical trials
were used to develop a decision tree with ﬁve treatment
alternatives: 1- and 2-year treatment with rimonabant, 2-year
placebo, 1-year rimonabant followed by 1-year placebo, and
no treatment. All alternatives, except no treatment, were
accompanied by lifestyle interventions. Treatment beneﬁts
included gains in quality-adjusted life-years (QALYs) and
reduced incidence of type-2 diabetes mellitus and coronary
heart disease (CHD). Drug acquisition cost was based on the
average wholesale price of a comparator drug minus 15%.
One-way and probabilistic sensitivity analyses were con-
ducted to assess the stability of the base-case results.
Results: One-year rimonabant and 1-year rimonabant fol-
lowed by placebo were extendedly dominated. Rimonabant
for 2 years showed an average weight reduction of 8.49 kg, a
body mass index reduction of 2.98 kg/m2 and reduced waist
circumference by 8.24 cm (placebo: 3.55 kg, 1.22 kg/m2,
4.18 cm). Two-year rimonabant was associated with a rela-
tive reduction in the 5-year incidence of CHD by 7.15% and
of diabetes by 9.28%. Incremental beneﬁts (costs) were
0.0984 QALYs ($5209) compared to no treatment and
0.0581 QALYs ($4182) compared to placebo, producing
ICURs of $52,936/QALY (95% conﬁdence interval $39K–
$69K) and $71,973/QALY ($51K–$98K), respectively.
Conclusions: Rimonabant combined with lifestyle interven-
tions has the potential to decrease the rate of obesity-related
comorbidities and improve health-related quality of life,
albeit at considerable cost.
Keywords: cost-utility, obesity, pharmacoeconomics, QALY,
rimonabant, weight loss.
Background
The increasing prevalence of obesity in the United
States and throughout the world imposes a serious
threat on the health of those inﬂicted and a large
burden to the health-care budgets of developed coun-
tries. In the United States, among persons aged
40–59 years, 73.1% are either overweight (body mass
index: the weight of the body in kilograms divided by
the square of its height in meters [BMI] > 25) or obese
(BMI > 30). The ﬁnancial burden of overweight in the
United States is estimated at $78.5 billion annually in
1998 ($97 billion in 2006 dollars) [1].
Extensive research has linked obesity to a wide
range of comorbidities including coronary heart
disease (CHD)and type-2diabetesmellitus [2–6].More-
over, even in the absence of comorbidities, obesity
signiﬁcantly impacts health-related quality of life
(HRQOL), mainly in the domains of physical func-
tioning and bodily pain. Weight reduction through a
variety of interventions is able to improve HRQOL
[7–9].
One type of intervention for weight reduction, bari-
atric surgery, is commonly restricted to morbidly obese
patients (BMI > 40) [10]; hence, not an option for
many overweight and mildly obese patients. For
patients with a BMI of >30 or >27 combined with
certain risk factors, pharmacologic treatment can
increase weight loss when added to dietary interven-
tions [11,12]. Currently, two pharmacologic agents are
FDA-approved for the indication of weight reduction:
sibutramine (Meridia, Abbott) and orlistat (Xenical,
Hoffman-La Roche). A third treatment option, rimo-
nabant (Sanoﬁ-Aventis), has received market authori-
zation in the European Union on June 21, 2006 [13],
and has since been introduced in more than 10 Euro-
pean countries and in Argentina, Chile, Brazil, and
Mexico as of May 2007. In the United States, rimona-
bant is currently under review by the FDA.
As the ﬁrst therapeutically relevant cannabinoid
(CB) antagonist, rimonabant selectively inhibits the
receptor subtype CB-1 of the endocannabinoid system
with a high afﬁnity in the central nervous system and a
lower afﬁnity in peripheral tissues including adipose
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tissue [14]. The inhibition of this receptor is associated
with an initial reduction in appetite and food intake, a
change in body composition, and a reduction in body
weight. Possible explanations for these effects, as sug-
gested by preclinical animal studies, include a central
stimulation of anorexia as well as an increase in energy
expenditure due to increased thermogenesis. Further-
more, changes in adipose tissue resulting in smaller
adipocytes are possibly mediated by peripheral mecha-
nisms [15,16].
To our knowledge, no study evaluating the phar-
macoeconomic implications of rimonabant has been
published to date. This study aimed to calculate the
incremental cost-utility ratio (ICUR) of rimonabant
compared to placebo, both combined with a lifestyle
intervention, and to a no-intervention alternative.
Modeled beneﬁts included gains in HRQOL due to a
temporary weight loss and a reduced incidence of the
comorbidities type-2 diabetes mellitus and CHD. The
model assumed the perspective of a third-party payer
in the United States.
Methods
Clinical Trials Data
This analysis employed data from three published
phase-III clinical trials on the efﬁcacy of rimonabant:
Rimonabant in Obesity (RIO) Europe, RIO-Lipids,
and RIO-North America [17–19]. All of the trials fol-
lowed a similar protocol; included were patients with
either BMI > 30 or BMI > 27 with treated or untreated
dyslipideamia or hypertension (RIO-Europe and
North America; RIO-Lipids: untreated dyslipidaemia
only). Patients were at least 18 years of age; exclusion
criteria and baseline characteristics were comparable
[17–19].
The trials were randomized, double-blinded,
placebo-controlled, parallel group, ﬁxed-dose, multi-
center studies with a 4-week single-blinded run-in
period with placebo. Following this period, patients
were randomized to placebo, 5 mg or 20 mg rimona-
bant to be taken once a day. In addition to drug
therapy, patients received lifestyle interventions includ-
ing a 600 kcal hypocaloric diet, dietician visits every
14 days for the ﬁrst month and every 28 days thereaf-
ter for the remainder of the study, and instructions to
increase physical activity. Results were reported after
12 months of treatment for RIO-Europe and RIO-
Lipids [17,18]; in RIO-North America, patients on
active treatment were re-randomized after 12 months
to either continue treatment or switch to placebo [19].
Findings from these clinical trials were pooled using
meta-analytic methods. We assessed heterogeneity in
the mean values of BMI, weight, and waist circumfer-
ence at screening and after 1-year for the treatment
and placebo groups using Cochran’s Q statistic
[19,20]. As none of the variables appeared signiﬁcantly
heterogeneous (P > 0.05) across trials, we employed a
ﬁxed effects model using the inverse squared standard
error as individual study weight [20].
Model Speciﬁcations
For this analysis, we used a decision tree (Fig. 1) com-
posed of ﬁve treatment arms which followed patients
for 5 years. The ﬁrst arm represented no intervention
(referred to as NNN, no intervention) and assumed
zero weight loss and no change in waist circumference
throughout the observation period (illustrated by the
gray horizontal line in Fig. 2). This assumption is con-
servative as weight is likely to increase over time
in obese patients [21]. The other arms replicated the
clinical trials: 2-year placebo (Fig. 2a, referred to as
PPN), 1-year rimonabant 20 mg (Fig. 2b, RNN),
1-year rimonabant 20 mg followed by 1-year placebo
(Fig. 2c, RPN), and 2-year rimonabant 20 mg (Fig. 2d,
RRN). Patients in all arms except the no-intervention
arm received lifestyle interventions while being on
placebo or rimonabant. Rimonabant 5 mg was not
included in this analysis because of its marginal efﬁ-
cacy as evidenced from the RIO trials. We included the
modeled arms to allow for a complete assessment of
the clinical trials although not all arms represent real-
istic treatment options (i.e., placebo). Our model con-
sidered a range of sustainability of weight loss from
6 months to 3 years, as described below. We chose a
time frame of 5 years based on the assumption that
any effects of treatment were limited to the period of
reduced weight (maximum 2 years of treatment and
3-year sustainability of weight loss).
Efﬁcacy Measures
Published data on baseline BMI, height, and weight
allowed for the calculation of average BMI at screen-
ing and after 12 months of treatment for each treat-
ment arm. We used these BMI values to calculate
changes in BMI related to each intervention. We cal-
culated standard errors of both BMI and BMI changes
from standard errors given for weight and height in the
three clinical trials and their covariance as derived
from RIO-Lipids, where BMI, weight, and height were
reported at a single time point [18]. To achieve this,
we utilized the delta method based on a ﬁrst-order
Taylor approximation which is a standard technique
to approximate expected values of a function, in this
case standard errors [22,23].
To develop the model of change in BMI over time
(Fig. 2), we assumed that weight loss during the ﬁrst
12 months of treatment approximated linearity to the
point of average weight loss in the respective arm.
The maintenance of reduced body weight during the
second year of treatment, as evidenced from RIO-
North America [19], was incorporated in the arms
PPN and RRN (Fig. 2a,d). In addition, we assumed a
linear weight regain to baseline after the end of the
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treatment. Information concerning sustained weight
loss after complete treatment cessation has not been
published for this intervention. Nevertheless, the UK
National Institute for Clinical Excellence (NICE) sug-
gests a period of 3 years of weight regain, back to
baseline values [24]. However, the rapid regain of body
weight after re-randomization to placebo in RIO-
North America suggests a return to baseline in a period
as short as 1 year after the end of the intervention [19].
We quantiﬁed the uncertainty in the sustainability esti-
mate in the sensitivity analysis. Change in waist cir-
cumference over time was calculated analogously to
change in BMI.
The impact of a reduction of BMI on health state
preferences has only been described for orlistat. Par-
ticipants in a randomized clinical trial of orlistat evalu-
ated their current health state preferences using a
visual analog scale [25]. Hakim et al. transformed the
derived value into the time trade-off estimate using the
Torrance transformation. A one-unit decrease in BMI
was associated with a 0.0170 gain in utility units
(referred to as utility transformation factor) which we
applied in our study. Furthermore, we assumed that
weight regain results in a decrease in quality of life to
the same extent as it had been improved by the pre-
ceding weight loss as suggested by Engel et al. [26].
We expressed change in utility over time as quality-
adjusted life-years (QALYs) which were calculated as
value of each health state (1 meaning best imaginable
health and 0 meaning death) multiplied by the time
spent in that health state. We ﬁrst calculated change in
BMI over time as area between the weight loss curve
Figure 1 Decision tree: Five arms represent four different treatment options and one no-intervention option. Possible outcomes include coronary heart
disease (CHD) and diabetes.The incidences of the outcomes were treated independently; i.e., the probability of experiencing both CHD and diabetes was
calculated by multiplying the incidence of diabetes by the incidence of CHD. NNN, no intervention; PPN, 2-year placebo; RNN, 1-year rimonabant; RPN,
1-year placebo; RRN, 2-year rimonabant.
Rimonabant Cost-Utility 391
and zero weight loss as illustrated in Figure 2 and
multiplied the result by the utility transformation
factor to achieve QALYs gained.
Changes in Incidences of CHD and Type-2
Diabetes Mellitus
A reduction in BMI is associated with a reduced inci-
dence of type-2 diabetes mellitus [27]. We modeled
change in BMI as described previously and its associa-
tion with the annual incidence of diabetes using the
results of two observational studies. Wannamethee
et al. reported the association of BMI with the inci-
dence of type-2 diabetes in men in the British Regional
Heart Study [27]. Estimates for women were calcu-
lated using the results of the Nurses’ Health Study
[28]. Plotting diabetes incidence versus BMI in the
range of 25 to 40 suggested a linear association which
was then quantiﬁed using linear regression. We found
that a one-unit increase in BMI was associated with an
increase of the annual incidence of diabetes by 0.098%
for men and 0.073% for women. These estimates were
weighted to reﬂect the sex composition in the rimona-
bant trials resulting in an estimate of 0.079% for our
model. To illustrate the incidence calculation, a BMI
reduction of 3 over 1 year from baseline BMI would be
equated with an entire year spent at a BMI of 1.5
below baseline. We would then multiply 1.5 with
0.079% to calculate the reduced diabetes incidence for
that year.
Change in waist circumference was used to predict
change in the incidence of CHD (deﬁned here as fatal
and nonfatal myocardial infarction [MI]), as waist cir-
cumference has been shown to be a better predictor of
CHD than BMI [29–31]. Rexrode et al. calculated the
risk for CHD in different categories of waist circum-
ference for men using data from the Physicians’ Health
Study and for women using data from the Nurses’
Health Study [6,32]. We used these results to calculate
the change in CHD incidence per centimeter change in
waist circumference analogous to the calculation of
diabetes incidence per change in BMI as described
above. For men, a 1 cm increase in waistline was asso-
ciated with a 0.01140% increase in the annual inci-
dence of CHD; for women, 0.00308%. This resulted
in a pooled estimate of 0.00503%.
We were unable to locate any published information
describing the conjoint probability of experiencing
comorbidities, CHD, and diabetes, as a function of BMI
or waist circumference. Therefore, the incidences of
CHD and diabetes were treated as being independent;
that is, the joint incidence of CHD and diabetes was
calculated as the product of the individual rates.
Economic Data
At the time of the analysis, rimonabant was not on the
US market; therefore, we had to estimate drug acqui-
sition cost. We used the cost of standard doses of
currently approved drugs, orlistat, and sibutramine,
to estimate daily treatment cost [33]. The cost of the
higher-priced drug, orlistat, was used in the base-case
scenario. The publicly available price for prescription
drugs in the United States is the average wholesale
price (AWP). This price, however, does not reﬂect
actual payments; rather, it is the basis for discounted
rates negotiated by different payers [34]. We calculated
drug acquisition cost as AWP minus 15% to reﬂect
expenditures of a third party excluding patients’
co-payments and varied our cost estimate in the sensi-
tivity analysis [35–37].
Other costs related to the intervention included
direct medical costs of dietary counseling and physician
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Figure 2 Reduction in body mass index (BMI) over time with different
treatment options. The gray straight line depicts a projected consistent
BMI for the no-intervention arm; the black line illustrates the mean change
in BMI of patients receiving the respective intervention; the gray-shaded
area covers times to weight regain included in the sensitivity analysis
(0.5–3 years). Screening and Intervention on the y-axis represent BMI at
the time of screening and BMI for the maximal average reduction due to
the intervention, respectively.N, no intervention; P, placebo,R, rimonabant.
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visits. The clinical trials reported 14 dietician visits in
the ﬁrst year.Our cost estimate for a single dietician visit
($30) represented the maximum allowable cost for a
15-minute session paid by the Medical Assistance
Administration in the state of Washington [38]. The
RIO trials did not report the number of physician ofﬁce
visits. Nevertheless, based on the reporting of labora-
tory values, bloodwas drawn at least ﬁve times per year.
Following that, we assumed one initial (20 min) and
four annual follow-up visits (10 min each) in our analy-
sis. The longer initial physician visit was assumed only
in the ﬁrst year. Cost estimates for physician visits were
$64 for a 20-minute visit and $36 for a 10-minute visit
as paid by Medicare (Current Procedural Terminology
[CPT] codes 99201 and 99201) [Available from: http://
catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?
checkXwho=done].
The base-case scenario for PPN, RPN, and RRN
assumed a 3-year period of reduced weight (2-year
treatment and 1-year sustainability as illustrated with
the black line in Fig. 2a,c,d). The symmetry of the
base-case BMI curves allowed us to keep the model
parsimonious, by assuming that comorbidities occurred
in the middle of this period, that is, after 1.5 years.
Thus, a patient with new onset diabetes would incur
treatment costs for the rest of this period (1.5 years).
Similarly, for a CHD event, we assumed cost for a
nonfatal MI with initial event costs and treatment costs
for 1.5 years post MI [39]. We did not include lifetime
treatment costs because we assumed that once patients’
weights returned to their baseline values, their subse-
quent risk of CHD and diabetes was equal to the risk
among nontreated patients. Thus, any cost-savings
associated with reduced CHD and diabetes were as-
sumed to be temporary, together withweight reduction.
Base-case cost estimates and ranges as well as
sources of the information used in the analysis are
presented in Table 1. All cost estimates were inﬂated to
represent 2006 US dollars using the medical care com-
ponent of the Consumer Price Index [Available from:
http://www.bls.gov/cpi/]. Costs and beneﬁts accruing
after the ﬁrst year were discounted at an annual rate of
3% [40].
Cost-Utility Analysis
The main outcome measures of this study were ICURs
of treatment with rimonabant compared to placebo
and to no intervention. The ICUR generally describes
the costs associated with achieving an additional unit
of treatment beneﬁt. ICURs were calculated as the
difference in costs between the intervention and the
alternative divided by the difference in QALYs gained
and were reported as $/QALY. After ranking treat-
ment options based on their ICURs, we eliminated
dominated options, as well as extendedly dominated
options. An option was considered dominated if it was
both more expensive and less effective than the alter-
natives. Extended dominance describes the phenom-
enon when the ICUR of a given treatment is higher
than the ICUR of the next, more effective option [40].
Sensitivity Analyses
To quantify the uncertainty in the model parameters,
we conducted a probabilistic sensitivity analysis using
Monte Carlo simulation. The model was recalculated
10,000 times, where each of the parameter estimates
was sampled from its distribution for each model
recalculation [41]. We modeled sustainability of
weight loss, drug cost, cost of MI, and cost of diabetes
as lognormal distributions. Triangular distributions
were used to model probabilities. We empirically deter-
mined input parameters for distributions to achieve
sample distribution means approximating the base-
case estimates (Table 1).
In addition, we conducted one-way sensitivity
analyses to examine the impact of a variation in single
parameters on the resulting ICUR. For selected vari-
ables, ranges of estimates were extended beyond the
values provided in Table 1 to model the impact of even
more extreme values on the ICUR; for example, the
sensitivity analysis was conducted for drug costs up to
$10/day (Fig. 5).
We pooled summary data from the clinical trials
using RevMan Analyses 1.0 (Review Manager,
Oxford, England). The decision tree, including sensi-
tivity analyses, was programmed in TreeAge Pro2004
(TreeAge Software Inc., Williamstown, MA, USA).
Results
Clinical Data
Data from the three pivotal clinical trials were pooled,
and a total of 3418 patients (1254 receiving placebo
and 2164 receiving rimonabant 20 mg) were included
in this analysis [17–19]. Patients were predominantly
female (76.6%), white (87.4%; information on race
only available for RIO-Europe and RIO-North
America), and on average 45.5 years old. At screening,
patients had an average BMI of 37.1, a mean body
weight of 103.5 kg, and a mean waist circumference of
108.2 cm.
We found that 2-year placebo combined with lif-
estyle interventions resulted in an average weight loss
from screening of 3.55 kg (95% conﬁdence interval
[CI] 3.25–3.85), a BMI reduction of 1.22 (95% CI
1.04–1.40), and a waist reduction of 4.18 cm (95%
CI 3.81–4.55). One-year treatment with rimonabant
20 mg reduced the average weight by 8.49 kg (95% CI
8.13–8.85), BMI by 2.98 (95% CI 2.76–3.19), and
waist circumference by 8.24 cm (95% CI 7.95–8.54)
(Table 1, weight reduction not shown).
Impact on CHD and Diabetes Incidence
Our model computed the 5-year cumulative incidence
of CHD without any intervention as 1.16% (116 per
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10,000 persons at risk). This incidence was reduced
by 0.042% (4.2/10,000) with placebo (relative risk
reduction [RRR]: 3.23%) and by 0.083% (8.3/10,000)
with 2 years of rimonabant (RRR: 7.15%). For the
no-intervention group, the 5-year cumulative incidence
of type 2 diabetes mellitus was 5.06% (506/10,000),
reduced by 0.192% (19.2/10,000) with placebo (RRR:
3.80%) and by 0.470% (47/10,000) with rimonabant
(RRR: 9.28%).
Cost-Utility Analysis
The treatment options RNN and RPN were extend-
edly dominated by the remaining options, PPN, RRN,
and NNN. Therefore, the options RNN and RPN were
not included in further analyses.
The cost-utility analysis of RRN (2-year treatment
with rimonabant) showed incremental costs of $5209
and incremental effectiveness of 0.0984 QALYs com-
pared to no intervention, resulting in an ICUR of
$52,936/QALY (95% CI $39K–$69K). Compared to
PPN (2-year placebo), incremental costs of RRN were
$4182 with an incremental effectiveness of 0.0581
QALYs, yielding an ICUR of $71,973/QALY (95% CI
$51K–$98K) (Table 2).
Sensitivity Analysis
Applying a probabilistic sensitivity analysis, compared
to NNN, RRN was cost-effective at $50,000/QALY in
40.2% of the simulations and compared to PPN in
only 1.6% (Fig. 3). An array of acceptability curves for
the comparison of RRN and NNN allows for the
applicability of the results to different daily drug cost
estimates at different willingness-to-pay thresholds
(Fig. 4). It shows, for instance, that almost all simula-
tions would show cost-effectiveness at $50,000/QALY
if the daily drug cost was $4.00.
The one-way sensitivity analyses identiﬁed vari-
ables where a variation had a considerable impact on
the ICUR. Critical variables were: daily drug cost,
change in BMI, sustainability of weight loss, and utility
Table 2 Results: cost-utility ratios of base-case scenario (for a single patient)
RRN PPN NNN RRN-PPN RRN-NNN
Costs
Drug cost 4,222.75 0.00 0.00 4,222.75 4,222.75
Physician cost 347.80 347.80 0.00 0.00 347.80
Dietician cost 711.26 711.26 0.00 0.00 711.26
Cost CHD 264.46 274.50 284.83 -10.04 -20.37
Cost diabetes 514.00 545.05 566.58 -31.06 -52.58
Total costs 6,060.27 1,878.61 851.41 4,181.66 5,208.85
Quality of life 0.00 0.00
QALYs gained 0.0984 0.0403 0.0000 0.0581 0.0984
Incremental cost-utility ratio* 71,973.43 52,935.52
95% conﬁdence interval† (51K-98K) (39K-69K)
*In $ per QALY.
†From Monte Carlo simulation.
Note:All costs in 2006 US$.
CHD, coronary heart disease; NNN, no intervention; PPN, 2-year placebo; QALY, quality-adjusted life-year; RRN, 2-year rimonabant.
Figure 3 (a) Distribution of incremental cost-utility ratios from Monte
Carlo simulation: rimonabant (RRN) vs. no intervention (NNN). The
scattered line represents the commonly used $50,000/QALY threshold;
points above would not be cost-effective at this threshold. (b) Distri-
bution of incremental cost-utility ratios from Monte Carlo simulation:
RRN vs. placebo (PPN). Points above would not be cost-effective at this
threshold. QALY, quality-adjusted life-year; incremental cost in 2006 US$.
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transformation factor. Variables that somewhat
affected the ICUR over no intervention were physician
and dietician cost. The remaining variables had no
major impact on the ICUR (Fig. 5). Because waist cir-
cumference is highly correlated with BMI [29], we
conducted a sensitivity analysis where both variables
were varied simultaneously. The combined inﬂuence of
both variables on the ICUR, however, resembled the
inﬂuence of change in BMI alone.
Discussion
Two-year treatment with rimonabant 20 mg in con-
junction with lifestyle intervention is efﬁcacious in
reducing body weight, BMI, and waist circumference.
It also has the potential to reduce the incidence of
obesity-related comorbidities such as CHD and dia-
betes mellitus, and consequently improve HRQOL.
These improvements are related to considerable expen-
ditures and have to be viewed in the context of alter-
native interventions to manage obesity. For orlistat in
the United Kingdom, Foxcroft et al. reported a cost-
utility ratio of £24,431/QALY (sensitivity range:
£10,856–77,197/QALY) [42]. In Ireland, orlistat has
shown to be cost-effective at U20AC; €16,954/QALY
(range: U20AC; €11,000–35,000/QALY) [43]. Hertz-
man found a cost-utility ratio of U20AC; €13,125/
QALY in Sweden and Maetzel et al. reported $8327
per event-free life-year gained in their US model
[44,45]. The cost-utility ratio of the second phar-
macologic alternative, sibutramine, was estimated at
$9299/QALY [46]. The wide range of cost-
effectiveness estimates for pharmacologic weight-loss
interventions is due partly to different underlying as-
sumptions across the studies, including ours, such
as the inclusion of comorbidities and the use of a
treatment-responder approach (described below). Fur-
thermore, time to weight regain after treatment cessa-
tion in previous studies is typically 3 years; however,
the clinical trials on rimonabant suggest a shorter sus-
tainability of 1 year. Variation in sustainability consid-
erably impacts the ICUR as the results of the sensitivity
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ent willingness-to-pay thresholds; each curve
for a separate daily drug cost estimate. QALY,
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mass index; CHD, coronary heart disease; MI, myocardial infarction; NNN, no intervention; QALY, quality-adjusted life-year; RRN, 2-year rimonabant.
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analysis indicate (Fig. 5). Increasing sustainability to
3 years would reduce the ICUR for rimonabant versus
no intervention to $35,394/QALY.
Another factor to be taken into consideration is that
medical costs, especially drug acquisition costs, differ
widely between Europe and the United States. The
daily cost for orlistat in the United Kingdom as used by
Hertzman [46] is about half the AWP of orlistat in the
United States. This difference is likely to contribute to
lower ICURs as the results of a variation in daily drug
costs in our sensitivity analysis suggest (Fig. 5).
Some of the studies above used the so-called treat-
ment responder approach which may partly account
for lower ICURs. This approach, as included in the
orlistat guideline of NICE in the United Kingdom,
recommends treatment with orlistat only if a patient
shows an initial weight loss with diet and exercise
alone [24]. Once initiated, physicians may only con-
tinue treatment if the patient successfully loses 5% of
body weight after 3 months and 10% after 6 months.
Hence, this treatment algorithm targets the interven-
tion to patients for whom the drug is likely to show
a higher effectiveness, avoiding drug costs associated
with nonresponse. In our study, however, we employed
data of clinical trials’ intention-to-treat population, a
population in which not every patient successfully ﬁn-
ished the treatment course. Using the treatment
responder approach for pharmacoeconomic studies is
likely to show more favorable cost-utility ratios due to
increased effectiveness. The difference in ICURs based
on the approach chosen is obvious in the case of orl-
istat where Foxcroft and Milne reported an ICUR
of £45,881/QALY without a treatment responder
approach [47], and in 2005, Foxcroft reported
£24,431/QALY using the treatment responder
approach [46].
We did not model the treatment responder
approach because of the lack of information contained
in the clinical trials publications and more so because
it is unclear whether a similar treatment guideline
would be used for rimonabant in the United States.
Again, the sensitivity analyses showed the impact of
a potential increase in average effectiveness on the
ICUR. If, for instance, the BMI could be lowered by
4 kg/m2, the ICUR would be reduced to $39,267/
QALY compared to no intervention. A treatment
responder approach is presumably associated with
triage costs resulting from the need to evaluate treat-
ment success. Yet, the sensitivity analysis showed that
the cost of physician ofﬁce visits only marginally
impacts the ICUR, and should therefore not be a
hurdle in the implementation of this approach.
Our model suggests that the largest beneﬁt to treat-
ment with rimonabant is an improvement in quality of
life. Cost-savings due to prevented comorbidities are
present, but fairly small (about 1.4%) compared to the
treatment costs (derived from Table 2). This conclusion
is supported by the sensitivity analysis (Fig. 5) which
shows that changes in variables related to comorbidities
(waist change, change in diabetes incidence per BMI,
change in CHD incidence per cm waist change, and
costs of diabetes and MI) have a minor impact on the
ICUR. This observation is associated with a relatively
low baseline incidence of CHD and diabetes over the
observation period. Even a considerable relative
decrease in the 5-year incidence of diabetes (9.28%)
translates into a smaller absolute decrease due to the
low baseline incidence. At an absolute decrease in dia-
betes risk of 0.47%, about 213 patients need to be
treated for 2 years to prevent the occurrence of one case
of diabetes in 5 years. This estimate is based on the
assumption that the decrease is solely associated with
the reduction in BMI. Similarly, the baseline cumulative
incidence of CHD over 5 years (1.16%) was associated
with a relative decrease by 7.15% with 2 years of
rimonabant, which translates into an absolute decrease
of 0.083% or 1205 patients needed to be treated to
prevent one event. Our model did not include disutility
values associated with CHD and diabetes; however, the
low incidences of these comorbidities suggest that the
impact of comorbidities on the overall quality of life in
this study would be very small.
The results of this study should be interpreted with
several limitations in mind. First, the model was based
on clinical trials where the efﬁcacy of the intervention
is generally determined in a controlled environment in
which patients may adhere and react differently to the
intervention because they are aware that they are part
of a study (Hawthorne effect). Patients in efﬁcacy trials
usually represent a homogenous population with only
limited variability in characteristics and comorbidities
which may increase the response to treatment [48].
Basing studies on the effectiveness of the drug under
general practice conditions should be an objective of
future economic analyses.
Second, the utility transformation factor used to
calculate the impact of weight reduction on quality of
life is based on a different drug, orlistat. In the re-
ference study, however, data were pooled over the
placebo and treatment arms [25]. Thus, it is reasonable
to argue that the gain in quality of life is attributed to
the reduction in BMI itself rather than to the means of
reduction and is therefore applicable to our scenario.
Nevertheless, because of the large impact on the ICUR
in our model, a utility transformation factor estab-
lished for the treatment with rimonabant should be
used on availability.
Third, because rimonabant was not on the US
market at the time of conducting the study, the drug
acquisition cost had to be estimated based on similar
drugs. However, the monthly cost for rimonabant in
the United Kingdom is £55.20 [49], about £10 above
the monthly cost for orlistat used by Foxcroft [42].
This supports our assumption that the likely acquisi-
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tion cost in the United States is covered by the price
range used in our model which is based on US costs for
orlistat.
Fourth, we assumed that weight loss and reduction
in waist circumference reduce the incidence of diabetes
and CHD, respectively. Yet, only the study by Wan-
namethee et al. showed a longitudinal relationship
between weight loss and a reduction in the incidence of
diabetes [27]. The other three studies used to estimate
disease incidences only reported cross-sectional asso-
ciations. For instance, Hu et al. reported that a lower
BMI level is associated with lower risk for diabetes in
women [28]. Similarly, Rexrode et al. [6,32] assessed
the cross-sectional association between waist circum-
ference at one point in time and CHD risk. We were
unable to identify any longitudinal studies which
established a causal relationship between changes in
waist circumference and a reduced incidence of CHD.
Finally, recent research has suggested that the
beneﬁt of treatment with rimonabant on obesity-
related diseases goes beyond what can be explained by
weight loss alone [50,51]. Improvements in HbA1c,
HDL-cholesterol, and triglycerides independent from
weight loss and their impact on comorbidities were not
included as beneﬁts in our model and are subject to
future research.
These results allow for several policy implications.
The high impact of drug acquisition cost on the cost-
utility ratio suggests that the ICUR can vary signiﬁ-
cantly between different purchasers in the United States
who pay different fractions of the AWP. In addition, the
ICUR is highly inﬂuenced by measures of efﬁcacy, with
a higher BMI reduction leading to more favorable
ICURs. A treatment responder approach as suggested
by NICE for Orlistat can help target the intervention to
patients where the drug promises a higher effectiveness
and thus improve cost-effectiveness. Finally, if an
increase in sustainability of weight loss could be
achieved, perhaps with ongoing lifestyle interventions
after pharmacologic treatment, the beneﬁts could be
extended. If this extension is feasible at reasonable cost,
a lower ICUR may be the result.
Conclusion
Rimonabant has shown to be efﬁcacious in reducing
excess body weight with the potential to decrease the
rate of obesity-related comorbidities and improve
health-related quality of life, albeit at considerable
cost. Future analyses should include real-world effec-
tiveness data, market prices of rimonabant, and ben-
eﬁts not explained by weight loss alone.
Special thanks to Dr Almut Winterstein for her valuable
input in the pooling of clinical trials data.
Source of ﬁnancial support: None.
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